Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMajed AltarebRKRajat KumarJMJonas Mattsson

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved relapse risk stratification in Acute Myeloid Leukemia post allogeneic stem cell transplantation, indicating the importance of MRD and chimerism assessment.

Key Points

  • D60 measurable residual disease assessment correlated with lower relapse risk in Acute Myeloid Leukemia patients post-transplant.
  • Primary graft failure occurred in 2.9% of patients undergoing allogeneic stem cell transplantation.
  • Evaluations included MRD levels at pre-transplant and day 60, alongside T-cell chimerism at day 30, used for risk stratification.
  • Highlights the need for further research into graft-versus-host disease prophylaxis impact on patient outcomes.

Cite This Study

Altareb et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5ebhttps://doi.org/10.1182/blood-2025-4295
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission2025
  2. 2Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations
  3. 3CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide2025
  4. 4Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial2025
  5. 5Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025